Article info

other Versions

PDF
Therapeutics
Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate

Authors

  1. Correspondence to Dr Graziella Filippini, Scientific Director’s Office, Carlo Besta Foundation and Neurological Institute, Milan 20133, Italy; graziella.filippini{at}istituto-besta.it
View Full Text

Citation

Filippini G
Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate

Publication history

  • Accepted August 27, 2017
  • First published November 8, 2017.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.